Entrada Therapeutics Reports 0.10% Mean Dystrophin Increase In 5 mg/kg Cohort Of Phase 1/2 Duchenne Trial Of ENTR-601-45; Primary Safety Goal Met
Share
Why It Matters
Entrada tested a new medicine for a serious muscle disease. The medicine was safe, but the improvement was very small so far.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.